Health Condition 1: 8- Other Procedures
Conditions
Interventions
Intervention1: Administration of intravenous Esmolol at a dose of 1.5 mg/kg: Participants are administered intravenous Esmolol at a dose of 1.5 mg/kg. Esmolol, a selective beta-1 adrenergic receptor a
Sponsors
Datta Meghe Institute of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: Participants meeting specific criteria were included in the study. These criteria encompassed individuals aged between 15 to 60 years, falling within American Society of Anesthesiologists (ASA) physical status classification I and II, scheduled for elective Ear, Nose, and Throat (ENT) surgical procedures. Additionally, inclusion required participants to have provided valid informed consent, ensuring their understanding and willingness to participate in the study. These criteria aimed to establish a homogeneous participant group suitable for the investigation into the comparative efficacy of intravenous Esmolol and 4% Lignocaine nebulization in attenuating haemodynamic responses during laryngoscopy and endotracheal intubation.
Exclusion criteria
Exclusion criteria: Participants were excluded from the study if they did not meet the predefined inclusion criteria, including age, ASA status, and surgical type. Additionally, individuals with anticipated difficult intubation, uncontrolled hypertension or diabetes, a history of cardiac illness, neuromuscular disorders, hepatic disease, renal disease, known sensitivity to the drugs under investigation, cerebrovascular disease, or undergoing emergency surgery were excluded. Furthermore, patients with bronchial asthma or those currently receiving alpha and beta blockers were also excluded from participation. These exclusion criteria were established to mitigate confounding factors and ensure the safety and integrity of the study outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome, attenuation of the hemodynamic stress response to laryngoscopy and endotracheal intubationTimepoint: The primary outcome, attenuation of the hemodynamic stress response to laryngoscopy and endotracheal intubation | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome of the study focuses on assessing the incidence of adverse events related to the study interventions and perioperative management. These adverse events may include hypotension, bradycardia, arrhythmias, or any other complications arising during the induction of anesthesia and endotracheal intubation proceduresTimepoint: This period begins from the administration of the study drugs (Esmolol or Magnesium Sulfate) and extends until the completion of the endotracheal intubation procedure. Adverse events are monitored continuously throughout this timeframe, allowing for the immediate identification and management of any complications that may arise during anesthesia induction and airway manipulation. | — |
Countries
India
Contacts
Public ContactDr Amol SIngham
Datta Meghe Institute of Higher Education and Research
Outcome results
None listed